Abstracts tagged "COVID-19"

Abstract Number: 1601 • ACR Convergence 2021
Satisfaction with Telemedicine in Immunosuppressed Children and Young Adults with Autoimmune Disease During the COVID 19 Pandemic: Are Their Needs Really Met? Preliminary Data from a Single Institution
Lakshmi Moorthy¹, Lauren Freidenrich¹, Lisa Mikesell², Sarah Fadem², Vikram Bhise¹, Richard Brodsky¹, Ellen Cahill¹, Joann Carlson¹, Yue Hao¹, Daniel Horton¹, Vivien Hsu¹, Editt Rodriguez¹, Christian Salazar³, Cynthia Salvant¹ and Lawrence Kleinman¹, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Department of Communication, New Brunswick, NJ, ³NYU Dept. of Epi. and Health Promotion, New York, NY
Background/Purpose: COVID-19 can lead to severe and life-threatening complications, which is particularly unnerving for patients with autoimmune disease (AID) on immunosuppressive therapy. Telemedicine has enabled…
Abstract Number: 1630 • ACR Convergence 2021
Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization
Lauren Covert¹, Mara Becker², Rebecca Sadun¹ and Heather Van Mater¹, ¹Duke University, Durham, NC, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a recently defined post-infectious phenomena associated with coronavirus disease 2019 (COVID-19). We assessed the demographics, clinical characteristics,…
Abstract Number: 0087 • ACR Convergence 2021
TNF Inhibitors and the Risk of Adverse COVID-19 Outcomes in Patients with Immune-Mediated Inflammatory Disease: Pooled Data from Three Global Registries
Zara Izadi¹, Erica Brenner², Satveer Mahil³, Nick Dand⁴, Zenas Yiu⁵, Mark Yates⁴, Ryan Ungaro⁶, Xian Zhang², Manasi Agrawal⁶, Jean-Frederic Colombel⁷, Milena Gianfrancesco¹, Kimme Hyrich⁵, Anja Strangfeld⁸, Loreto Carmona⁹, Elsa Frazão Mateus¹⁰, Saskia Lawson-Tovey⁵, Eva Klingberg¹¹, Giovanna Cuomo¹², Marta Caprioli¹³, Rene-Marc FLIPO¹⁴, Ana Rita Cruz-Machado¹⁵, Carolina Mazeda¹⁶, Rebecca Hasseli¹⁷, Alexander Pfeil¹⁸, Hanns-Martin Lorenz¹⁹, Laura Trupin²⁰, Stephanie Rush¹, Patricia Katz¹, Gabriela Schmajuk¹, Lindsay Jacobsohn²¹, Andrea Seet¹, Samar Al Emadi²², Leanna Wise²³, Emily Gilbert²⁴, Ali Duarte-Garcia²⁵, Maria Valenzuela-Almada²⁶, Carolina Isnardi²⁷, Rosana Quintana²⁷, Enrique Soriano²⁸, Tiffany Hsu²⁹, Kristin D'Silva³⁰, Jeffrey Sparks³¹, Naomi Patel³⁰, Viviane de Souza³², Licia Maria Henrique Mota³³, Ana Paula Reis³⁴, Zachary S. Wallace³⁵, Suleman Bhana³⁶, Wendy Costello³⁷, Rebecca Grainger³⁸, Jonathan Hausmann³⁹, Jean Liew⁴⁰, Emily Sirotich⁴¹, Paul Sufka⁴², Philip Robinson⁴³, Pedro Machado⁴⁴, Christopher Griffiths⁴⁵, Jonathan Barker⁴, Catherine smith⁴, Jinoos Yazdany¹ and Michael Kappelman², ¹University of California San Francisco, San Francisco, CA, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³St John’s Institute of Dermatology, London, United Kingdom, ⁴King's College London, London, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷MD, New York, NY, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ¹⁰Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ¹¹University of Gothenburg, Gothenburg, Sweden and Sahlgrenska University Hospital, Gothenburg, Sweden, ¹²Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy, ¹³IRCCS Humanitas Research Hospital, Milan, Italy, ¹⁴Rheumatology Department, Lille University Hospital, Lille, France, ¹⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹⁶Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ¹⁷Justus-Liebig-University Giessen, Bad Nauheim, Germany, ¹⁸Friedrich Schiller University Jena, Jena, Germany, ¹⁹University Hospital Heidelberg Germany, Heidelberg, Germany, ²⁰UC San Francisco, San Francisco, CA, ²¹University of California San Francisco, Antioch, CA, ²²Hamad medical corporation, Doha, Qatar, ²³LAC+USC/Keck Medicine of USC, Pasadena, CA, ²⁴Mayo Clinic, Jacksonville, FL, ²⁵Mayo Clinic, Rochester, MN, ²⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ²⁷Argentine Society of Rheumatology, Buenos Aires, Argentina, ²⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²⁹Brigham and Women's Hospital, Jamaica Plain, MA, ³⁰Massachusetts General Hospital, Boston, MA, ³¹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³²UFJF, JUIZ DE FORA, Brazil, ³³Universidade de Brasília, Brasilia, Brazil, ³⁴Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, ³⁵Harvard Medical School, Boston, MA, ³⁶Crystal Run Health, Montvale, NJ, ³⁷Irish Children's Arthritis Network, Bansha, Ireland, ³⁸University of Otago, Wellington, New Zealand, ³⁹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁴⁰Boston University, Boston, MA, ⁴¹McMaster University, Hamilton, ON, Canada, ⁴²HealthPartners, Eagan, MN, ⁴³University of Queensland School of Clinical Medicine, Brisbane, Australia, ⁴⁴Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁴⁵University of Manchester, Manchester Centre for Dermatology Research, Manchester, United Kingdom
Background/Purpose: While tumor necrosis factor inhibitors (TNFi) are widely prescribed globally due to their high efficacy across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19…
Abstract Number: 0105 • ACR Convergence 2021
Most Patients with Spondylitis Accept COVID-19 Vaccination and Few Experience Disease Exacerbation After Immunization
Rachel Higgins¹, Hedley Hamilton², Michael Weisman³, John Reveille⁴, Kimbery Ogle¹, Cassie Shafer⁵, Elin Aslanyan⁵, Richard Howard⁵, Dongseok Choi¹, James T. Rosenbaum⁶ and Kevin Winthrop¹, ¹Oregon Health & Science University, Portland, OR, ²Any-3 Ltd, London, United Kingdom, ³Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁵Spondylitis Association of America, Encino, CA, ⁶Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMDs) remain at an increased risk of morbidity and mortality from vaccine preventable infections, often as a result…
Abstract Number: 0266 • ACR Convergence 2021
The Psychosocial Impact of the COVID-19 Pandemic on the Rheumatology Patient Experience
Melissa Flores, Priscilla Toral, Roberta Horton, Adena Batterman, Mavis Seehaus, Juliette Kleinman and Jillian Rose, Hospital for Special Surgery, New York, NY
Background/Purpose: Research shows people with rheumatic conditions may be more susceptible to severe illness from COVID-19 due to their immunocompromised state. The COVID-19 pandemic has…
Abstract Number: 0826 • ACR Convergence 2021
Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19
Miao Wang¹, Sylvie Lardeux², Elisea Avalos-Reyes³, Michele Hamburger⁴ and Kjel Johnson⁵, ¹CVS Health, New York, NY, ²CVS Health, Wellesley, MA, ³CVS Health, Irving, TX, ⁴Frances Hamburger Institute, Hauppauge, NY, ⁵CVS Health, Lincoln, RI
Background/Purpose: During the COVID-19 pandemic, individuals were encouraged to shelter in place, specifically those considered high risk for COVID-19. Rheumatoid arthritis (RA) patients are known…
Abstract Number: 0990 • ACR Convergence 2021
Lower Incidence of COVID-19 but Higher Mortality in Patients with Inflammatory Arthritis Compared to Controls in Wales, United Kingdom: A Population Epidemiological Study
Roxanne Cooksey¹, Mark Atkinson² and Ernest Choy³, ¹Cardiff University, Cardiff, Wales, United Kingdom, ²Swansea University, Swansea, Wales, United Kingdom, ³CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: The COVID-19 pandemic has caused over 3 million deaths. Having inflammatory arthritis (IA) and anti-rheumatic medications increase the risk of infections. Comorbidities, common in…
Abstract Number: 1445 • ACR Convergence 2021
Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)
Namrata Singh¹, Chen Hu², Vithal Madhira², Kate Fitzgerald², Timothy Bergquist³, Kayte Anderson², Amy Olex⁴, Rena Patel⁵ and Jasvinder Singh⁶, ¹University of Washington, Bellevue, WA, ²Johns Hopkins, Baltimore, MD, ³Sage Bionetworks, Seattle, WA, ⁴Virginia Commonwealth University, Richmond, VA, ⁵UW, Seattle, WA, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with Rheumatoid arthritis (RA) are at a potentially increased risk of SARS-CoV-2 infection, and immunosuppressive or biologic drugs used to treat RA might…
Abstract Number: 1542 • ACR Convergence 2021
Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?
Andrew Laster¹, Gordon Lam¹, Sarah McCarter¹, Heather Gladue², Ahmad Kashif¹, Erin Siceloff¹, Victoria Lackey², Cheryl Robertson², Ashley Toci¹ and Leonard Calabrese³, ¹Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Clinical trials leading to approval of the COVID19 vaccines did not include immunocompromised individuals. Concerns have been raised that immunogenicity of the vaccines may…
Abstract Number: 1560 • ACR Convergence 2021
A Multidisciplinary Timely Approach to Initiate Immunosuppressive Biologic Therapy and Improve COVID-19 Cytokine Storm Syndrome Outcome
Anand Kumthekar¹ and Bibi Ayesha², ¹Albert Einstein College of Medicine, Bronx, NY, ²Montefiore Medical Center, Bronx, NY
Background/Purpose: Coronavirus disease (COVID-19) patients can progress to a state of unregulated inflammation called cytokine storm syndrome (CSS). A multi-disciplinary approach is needed to identify…
Abstract Number: 1602 • ACR Convergence 2021
Factors Associated with COVID-19 Vaccine Hesitancy in Rheumatology Outpatients in New York City
Medha Barbhaiya¹, Brandon Schneider², Jonah Levine¹, Huong Do¹, Caroline Siegel¹, Vivian Bykerk³, Candace Feldman⁴, Deanna Jannat-Khah¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: COVID-19 vaccination is particularly important for patients with systemic rheumatic diseases (SRDs), who may be at increased risk of infection with SARS-CoV-2 and of…
Abstract Number: 1637 • ACR Convergence 2021
Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience
Eric Kok, Martha Curry, Andrea Ramirez, Eyal Muscal and Marietta DeGuzman, Baylor College of Medicine, Houston, TX
Background/Purpose: Infection with novel coronavirus (COVID-19) in children, unlike adults, is generally asymptomatic or causes mild disease although some may develop severe illness. In particular,…
Abstract Number: 0089 • ACR Convergence 2021
SARS-CoV-2 Seroprevalence and Seroconversion in a Systemic Lupus Erythematosus Cohort and Comparison to General Population Controls
Hannah Mathew¹, May Choi², Katherine Buhler¹, Ann Clarke¹, Xenia Gukova¹, Francesca Cardwell³ and Marvin Fritzler¹, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ³University of Waterloo, Waterloo, ON, Canada
Background/Purpose: At the outset of the SARS-CoV-2 pandemic, it was speculated that SLE patients may be at significant risk of developing COVID-19 due to underlying…
Abstract Number: 0106 • ACR Convergence 2021
COVID-19 Mortality and Hospitalization Risk in Patients with Rheumatic Diseases: A Single Center Retrospective Cohort Study
Mousa Albalwi, Ben Brintz, Srinivasan Beddhu, Guo Wei and Julie Thomas, University of Utah, Salt Lake City, UT
Background/Purpose: Following SARS-CoV-2 infection, patients with rheumatic diseases seem to have similar or slightly poorer outcomes compared with those without rheumatic disease. However, robust data…
Abstract Number: 0267 • ACR Convergence 2021
Psychosocial and Health Measures in Systemic Lupus Erythematosus: Before and During the COVID-19 Pandemic in the Georgian’s Organized Against Lupus Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao¹, S Sam Lim² and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Disruptions of routines or livelihood and worry during the COVID-19 pandemic may have impacted systemic lupus erythematosus (SLE) patients in multiple ways. We explored…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].